PT  - JOURNAL ARTICLE
AU  - Jack Stone
AU  - Hannah Fraser
AU  - Josephine G Walker
AU  - Nyashadzaishe Mafirakureva
AU  - Bernard Mundia
AU  - Charles Cleland
AU  - Bartilol Kigen
AU  - Helgar Musyoki
AU  - Wanjiru Waruiru
AU  - Allan Ragi
AU  - Parinita Bhattacharjee
AU  - Nok Chhun
AU  - John Lizcano
AU  - Matthew J Akiyama
AU  - Peter Cherutich
AU  - Ann Kurth
AU  - Niklas Luhmann
AU  - Peter Vickerman
TI  - Modelling the Impact of Prevention and Treatment Interventions on HIV and Hepatitis C Virus Transmission Among People Who Inject Drugs in Kenya
AID  - 10.1101/2021.02.02.21251008
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.02.02.21251008
4099  - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21251008.short
4100  - http://medrxiv.org/content/early/2021/02/03/2021.02.02.21251008.full
AB  - Background People who inject drugs (PWID) in Kenya have a high prevalence of HIV (14-26%) and HCV (11-36%). Needle and syringe programmes (NSP) and antiretroviral therapy (ART) have high coverage among PWID, while HCV treatment and opioid substitution therapy (OST) access is low.Methods A dynamic model of HIV (sexual and injecting-related) and HCV (injecting-related) transmission among PWID was calibrated using Bayesian methods to data from Nairobi and the Coastal region. We projected the impact of existing coverage levels of interventions (ART: 64-66%; OST: 4-7%; NSP: 54-56%) in each setting, and the impact over 2020-2030 of increasing the coverage of OST (50%) and NSP (75%; ‘full HR’), ART (UNAIDS 90-90-90 target), HCV treatment (1000 over 5 years), and reducing HIV sexual risk by 75%. We estimated HCV treatment levels needed to reduce HCV incidence by 90% with or without full HR.Findings Since 2013, HR has averted 15.1-20.6% (range in medians across settings) of HIV infections and 29.0-31.6% of HCV infections across Nairobi and the Coastal region, with most impact being due to NSP. Conversely, ART has only averted <5% of HIV infections since 2004 because of sub-optimal viral suppression (28-48%). Going forward, Full HR and ART could reduce HIV incidence by 58.2-62.0% and HCV incidence by 62.6-81.6% by 2030 across these settings. If sexual risk is also reduced, HIV incidence would reduce by 77.1-81.4%. Alongside full HR, treating 896 PWID over 2020-2025 could reduce HCV incidence by 90% by 2030.Interpretation Existing interventions have had moderate impact on HIV and HCV transmission in Kenya, but may have substantial impact if scaled-up. However, to achieve HIV and HCV elimination, reductions in sexual risk are needed and a scale-up in HCV treatment.Funding Global Fund, MDMCompeting Interest StatementHF has received an honorarium from MSD unrelated to this research. PV and JGW have received unrestricted research funding from Gilead unrelated to this work. All other authors have no disclosures.Funding StatementThis study was funded by the Global Fund East Africa Harm Reduction Project and Medicins du Monde. JS, PV, and HF acknowledge support from the NIHR Health Protection Research Unit in Behavioural Science and Evaluation and from NIDA (R01AI147490). MJA acknowledges support from NIDA (R00DA043011). Funding for study data provided from AK and PC was from NIDA 5R01DA032080.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:None needed. This is a modelling study.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesModel code will be shared with researchers who provide a methodologically sound proposal approved by Dr Jack Stone and Professor Peter Vickerman. Proposals should be directed to jack.stone{at}bristol.ac.uk and Peter.vickerman{at}bristol.ac.uk; requesters will need to sign a data access agreement.